no need ledrog :-) all we need to know is that RVX is going after an orphan indication for which the current treatment costs $340k per year. Alexion makes close to $300m per year and that is from treating just 25% of the sufferers. (writing from memory so apols if I get the numbers a bit wrong; but the gist is right) Putting aside the potential implications from the recent political backlash on high drug pricing, basically orphan indications mean companies can charge very high prices. RVX is going after a piece of the action with multiple molecules and multiple indications.